We chose to test fisetin for a number of reasons: (a) fisetin is a dual inhibitor of both PI3K/Akt pathways [22], which is one of the major kinase for YB-1 phosphorylation, (b) fisetin inhibits mTOR pathway [23-24], which is now shown to be important for YB-1 mRNA translation [40] and based on our previous observations fisetin inhibits the growth of PCa. The gene discussed is AKT1; the disease is posterior cortical atrophy.